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Background: Solitary papillary muscle (PM) hypertrophy is an unique type of hypertrophic cardiomyopathy (HCM),
which is characterized by predominant papillary muscle hypertrophy sparing the rest of other left ventricular
segments. It has recently drawn our attention about the mechanism of left ventricular mid-cavity obstruction and
the influence of pressure gradient in the left ventricular outflow tract (LVOT), thus carries clinical importance.
Case presentation: We reported a symptomatic, 83-year-old woman who presented with dynamic, high resting left
ventricle (LV) mid-wall gradient without obvious septal hypertrophy or systolic anterior motion (SAM). Subsequent
real-time (RT) three-dimensional echocardiography (3DE) and cardiac magnetic resonance imaging (MRI)
demonstrated large, hypertrophic accessory papillary muscles squeezing mid-cavity of left ventricle producing
dynamic pressure gradient during systole in the absence of left ventricular wall anomalies.
Conclusion: We proposed that combined use of echocardiography particularly RT-3DE and cardiac magnetic
resonance imaging (MRI) can accurately identify this specific type of hypertrophic cardiomyopathy without
remarkable traditional features.
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Hypertrophic obstructive cardiomyopathy (HOCM) refers
to those subjects with significant dynamic left ventricular
outflow tract (LVOT) obstruction due to mechanical
causes, with most presents with asymmetrical septal hyper-
trophy resulting in dynamic systolic anterior motion (SAM)
of mitral leaflets [1].
Solitary papillary muscle (PM) hypertrophy, a peculiar
form of HCM manifested as predominant PM hyper-
trophy sparing the rest of other LV segments, has re-
cently gained much attention owing to its mechanical
consequences on left ventricular outflow tract (LVOT)
pressure gradient formation [2,3].* Correspondence: jotaro3791@gmail.com
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A 83-year-old woman with history of hypertension and
hyperlipidemia. The blood pressure and hyperlipidemia
were well-controlled with medication. She was admitted to
our hospital with chest pain on effort and exertional short-
ness of breath. Her vital sign was stable with blood pressure
131/70 mmHg and heart rate 67 beats per minute at initial
presentation. A mid-systolic ejection murmur was heard
along the left sternal border with chest X-ray showed minor
pulmonary congestion. Incidental high resting LV mid-wall
pressure gradient (86 mmHg, Figure 1A) was shown by 2-
dimensional echocardiography without LV septal wall thick-
ness (8.5 mm). The LV end-diastolic volume was 90 ml,
and LV end-systolic volume was 27 ml. Apparently hyper-
trophied anterolateral (A) and posteromedial (P) papillary
muscles together with a large, third accessory PM were
observed (Figure 1C). Neither aortic stenosis nor SAM
was observed. Complete ECG disclosed obvious U wavetd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
Figure 1 2D Echocardiography and complete ECG. (A) Continuous wave Doppler tracing of the LV mid-wall showed the peak pressure
gradient was 85.5 mmHg at rest. (B) Subsequent continuous wave Doppler tracing eight hours later showed normal pressure gradient (estimated
to be 5 mmHg). (C) In short axis view, apparently hypertrophied anterolateral and posteromedial papillary muscles together with a large, third
accessory PM were observed (A: anterolateral papillary muscle, P: posteromedial papillary muscle, ACC: accessory papillary muscle). (D) Complete
ECG showed prominent U wave in V1-V4.
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Blood level of B-natriuretic peptide was obviously elevated
(227 pg/ml).
Repeated 2D transthoracic echocardiogram during
hospitalization revealed no more pressure gradient (plum-
meted to 5 mmHg) after holding diuretics (Figure 1B).
Meanwhile, she was in euvolemic state with blood pressure
128/76 mmHg and heart rate 62 beats per minute. To fur-
ther clarify the spatial relationships between these hypertro-
phied PMs and other LV wall segments, real-time 3D
echocardiography (RT-3DE) was performed and showed
nearly complete LV mid-wall cavity obliteration by the
these morphological abnormal PMs during end-systolic
phase (Figure 2A-B; Additional files 1, 2 and 3). Subsequent
MRI study demonstrated normal LV volume (end-diastolic
volume: 71.9 ml), unremarkable LV wall abnormalities,
normal global LV mass index (79.9 gm/m2) though signifi-
cantly hypertrophied PMs (total PM mass: 20.2 gm;
13.4 gm/m2 indexed to body surface area; Figure 2C-D)
without visible perfusion defects or delayed hyperenhance-
ment (DHE). High temporal resolution Tissue Doppler
Imaging (>250 frames per second) further demonstrated
markedly diminished diastolic mitral annulus relaxation
velocities (1.8 cm/sec for basoseptal and 4.3 cm/sec for
basolateral segments; Figure 2E-F). When PMs mass were
taken into account (up to 16.8% LV mass; Figure 3A-B), the
total LV mass may reach the echocardiographic criteria for
LV hypertrophy [4] (defined as LV mass index >95 gm/m2in women and > 115 g/m2 in men). Beta-blockade was then
prescribed and the symptoms improved drastically during
the subsequent follow up.
Conclusions
So far, left ventricular hypertrophy remained the predomin-
ant and major phenotypic component of hypertrophied
cardiomyopathy [1]. Few cases of dynamic LVOT or mid-
cavity obstruction in relation to various morphological pap-
illary muscle anomalies had been reported before, and these
may include bifid [5] or octopus papillary muscle [6],
accessory [7], single [2], or solitary papillary muscle hyper-
trophy [8]. Papillary muscle hypertrophy, when defined by
at least one of the two papillary muscles is more than
1.1 cm in either vertical or horizontal diameter, had been
recently shown to be a phenotypic variant of HCM [8,9].
Not until recently, morphological papillary muscle anomal-
ies without features of phenotypic LV hypertrophy (isolated
papillary muscle hypertrophy) had gradually been recog-
nized to be an uncommon HCM variant [8,10]. The clinical
features of LV mid-cavity obstruction caused by papillary
muscle hypertrophy may vary greatly from asymptomatic
to dyspnea, angina, syncope, and even sudden cardiac death
[8-10], with prominent U wave and left ventricular hyper-
trophy by ECG [11,12], which is concordant with our
current case findings.
While HCM subjects with concomitant morpho-
logical papillary muscle anomalies may present with
Figure 2 Real 3D echocardiography, MRI, and tissue doppler imaging. (A) 2D echocardiogram in the short-axis section of the left ventricle
demonstrated uncommonly enlarged papillary muscles (A: anterolateral papillary muscle, P: posteromedial papillary muscle, ACC: accessory
papillary muscle). (B) Real time 3D Echocardiography demonstrated that LV mid-cavity was almost obliterated during end-systolic phase from five
chamber view (Additional file 1, movie 1). A: anterolateral papillary muscle, LA: left atrium, LV: left ventricle. (C) Contrast-enhanced MRI from LV
short-axis showed two large papillary muscles as well as adjacent abundant muscular trabeculae producing mid-cavity obstruction during systolic
phase. (D) MRI from long-views showed anterolateral papillary muscle squeezing left ventricular outflow tract against LV septum during systolic
phase. High temporal resolution Tissue Doppler Imaging showed markedly diminished diastolic mitral annulus relaxation velocities, 1.8 cm/sec for
basoseptal (E) and 4.3 cm/sec for basolateral segments (F).
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surprising that subjects with increasing number of
hypertrophied papillary muscles with unchanged ven-
tricular cavity size may have higher probability of
causing LV chamber obliteration during systole. So
far, there are reports presented with isolated papillarymuscle hypertrophy and normal LV wall thickness.
Herein, we report a case of morphological papillary
muscle anomalies featured by dynamic LV mid-wall
obstruction, with subjective exertional chest pain and
dyspnea. We further observed in our case that se-
verely impaired LV diastolic function and clinical
Figure 3 Cardiac MRI, short axis view. (A) Unremarkable LV wall abnormality with normal LV mass at end-diastolic phase by MRI; (B)
Hypertrophy PMs as well as existence of accessory PM (ACC) shown.
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cessive, redundant papillary muscle mass with normal
LV mass [7].
Current guidelines for LV mass calculation do not take
papillary muscle mass into account, while our relevant
findings may suggest include papillary muscles in LV
mass assessment, especially for these morphologically
abnormal papillary muscle subjects.
Solitary papillary muscle hypertrophy as an uncom-
mon variant form of HCM with coexisted additional,
accessory papillary muscle may develop abnormally high
resting LV mid-wall pressure gradient without SAM or
significant regional LV wall hypertrophy. Cardiac MRI
and RT-3DE may have their peculiar roles in uncovering
these cardiac morphological/structural anomalies aiming
for a more comprehensive analysis on their spatial
relationships.
In conclusion, we recommended that for subjects with
unusually high LV mid-wall or LVOT pressure gradient
with unrevealing regional LV segment anomalies, RT-
3DE and MRI should be considered as a screening tool
to disclose these under-diagnosed, specific HCM sub-
jects in daily routine.Consent
Written informed consent was obtained from the patient
for publication of this Case report and any accompanying
images. A copy of the written consent is available for review
by the Editor-in-Chief of this journal.Additional files
Additional file 1: Real time 3D Echocardiography, four chamber
view.Additional file 2: Real time 3D Echocardiography, short axis view.
Additional file 3: Real time 3D echocardiography sequences in
short axis view, divided the left ventricle into 9 slices during
end-diastolic phase.
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